Healthcare / BiotechnologyNasdaqCM
$6.12
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-13.0M · quality 61.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
1/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$42M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-560.2%
↓Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
-0.7%
FCF CAGR
—
FCF margin
-399.8%
FCF / Net income
0.93x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.2M · net income $-22.4M · FCF $-20.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $5.2M | $5.2M | $5.8M | $4.9M | — | — | — | — | $3.7M | $2.7M | $4.7M | $4.8M | $5.0M | $7.1M | $8.7M | $8.0M | $8.3M | $5.8M |
| Net Income | $-22.4M | $-22.4M | $-13.0M | $-13.3M | $-20.3M | $-13.4M | $-8.2M | $-10.9M | $-12.6M | $-22.7M | $-22.0M | $-18.7M | $-37.4M | $-26.2M | $-32.3M | $-32.5M | $-27.5M | $-23.2M |
| EBITDA | $-14.9M | $-14.9M | $-13.8M | $-12.7M | $-19.1M | $-12.1M | $-9.2M | $-2.8M | $-6.8M | $-18.5M | $-18.5M | $-14.2M | $-31.7M | $-29.0M | $-27.5M | $-28.6M | $-24.4M | $-19.9M |
| EPS | -0.29 | -0.29 | -2.34 | -4.24 | -11.58 | -1.11 | — | — | — | — | — | — | — | — | — | -0.61 | -0.60 | -0.65 |
| Gross Margin | — | — | — | — | — | — | — | — | — | 5.4% | 41.7% | 34.1% | 40.6% | 52.0% | 54.1% | 51.9% | 52.7% | 41.9% |
| Operating Margin | -293.5% | -293.5% | -252.3% | -271.1% | — | — | — | — | -238.7% | -769.2% | -423.2% | -316.0% | -654.9% | -430.8% | -326.3% | -368.4% | -306.8% | -369.1% |
| Net Margin | -429.4% | -429.4% | -222.8% | -271.0% | — | — | — | — | -344.2% | -843.7% | -473.5% | -387.4% | -754.5% | -367.6% | -370.6% | -406.5% | -333.1% | -397.7% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | — | — | — | — | 0.59 | 0.46 | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-20.8M | $-20.8M | $-10.7M | $-13.0M | — | — | — | $-6.0M | $-12.1M | $-18.4M | — | — | — | $-35.1M | $-33.4M | $-35.9M | $-24.2M | $-24.0M |
| Returns | ||||||||||||||||||
| ROE | -560.2% | -560.2% | 145.0% | 987.8% | -314.6% | -123.7% | -271.9% | -938.5% | -241.8% | -174.5% | -200.7% | -153.6% | 655.3% | -835.8% | -500.1% | -326.3% | -120.2% | 634.7% |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | -10.5% | -10.5% | 18.5% | — | — | — | — | — | 36.5% | -42.2% | -3.8% | -2.3% | -30.5% | -18.2% | 9.1% | -3.3% | 41.4% | — |
| EPS Growth | 87.6% | 87.6% | 44.8% | 63.4% | -943.2% | — | — | — | — | — | — | — | — | — | — | -1.7% | 7.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.